Investigational Drug Details
| Drug ID: | D588 |
| Drug Name: | Momelotinib |
| Synonyms: | CYT-387; GS-0387; Momelotinib dihydrochloride |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | ACVR1 protein inhibitors; Janus kinase 1 inhibitors; Janus kinase-2 inhibitors |
| Therapeutic Category: | Antineoplastics; Antirheumatics |
| Clinical Trial Progress: | -- |
| Latest Progress: | Under investigation |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A06024 | 33036387 | Cells | Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings. | Details |
| A51167 | 35395857 | J Exp Clin Cancer Res | The role of TBK1 in cancer pathogenesis and anticancer immunity. | Details |